A team of the Institute of Biomedicine and Molecular Immunology (IBIM) of the CNR, directed by Marta Di Carlo, in collaboration with chemistry engineers and biophysics of Palermo, have developed a new nanosystems (nanogel) able to vehicle insulin to the brain, via intranasal administration, overcoming the limits related to peripheral administration, that could lead to hyperinsulinemia. Patients affected by Alzheimer’s disease (AD) develop insulin resistance a condition that is considered a risk factor to develop AD and also referred as Type 3 Diabetes. The new bioengineered product has been tested for its biocompatibility, hemocompatibility, neuroprotectionand ability to overcome the Blood Brain Barrier. To obtain a commercial product, additional preclinical studies will be carried out that includeapplication of Good Manufacturing Practices (GMP) in according to a Quality Management System (QMS).